The global probiotics market, valued at USD 70.9 billion in 2024, will reach USD 76.2 billion in 2025 and is on track to hit USD 165.1 billion by 2035, growing at a CAGR of 8.0% over the forecast period. That trajectory reflects a fundamental shift in how consumers, healthcare providers, and food manufacturers think about gut health, preventive nutrition, and immune support across all age groups.
To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/probiotics-market/request-sample.html
Market Overview: From Functional Foods to Precision Nutrition
Probiotics are live, non-pathogenic microorganisms that, when consumed in adequate quantities, confer measurable health benefits to humans and animals. Long associated with fermented dairy, these microorganisms now reach consumers through a broad product spectrum: beverages, dry foods, nutritional supplements, specialty supplements, infant formula, and animal feed. Their commercial appeal has grown because they occupy a rare space, delivering science-backed benefits without being perceived as pharmaceuticals.
The post-pandemic period has been particularly formative for this market. Health-conscious consumers accelerated their adoption of daily wellness regimens, and probiotics fit naturally into that shift. Heightened awareness of gut-brain interactions, immune function, and the role of microbiome balance in preventing chronic disease has expanded the potential consumer base well beyond the traditional digestive health buyer. Probiotics now intersect with mental health research, pediatric medicine, dermatology, and women’s health, broadening the commercial surface significantly.
Recent industry activity reinforces this momentum. In August 2024, ZBiotics completed a USD 12 million Series A funding round to advance commercialization of genetically engineered probiotics. In July 2024, Kaneka Probiotics and AB-BIOTICS launched Gyntima Menopause, a probiotic blend targeting hormonal balance in peri- and post-menopausal women. And in July 2025, ClostraBio secured GRAS status for its next-generation probiotic strain, Anaerostipes caccae CLB101TM, a regulatory milestone that opens new doors for clinical and consumer applications.
Key Growth Drivers
Rising Consumer Awareness Around Preventive Health Post-COVID, consumers in major markets began treating gut health as a first line of defense rather than an afterthought. According to IFIC’s 2021 Food and Health Survey of 1,000 US adults, 67% were familiar with probiotics and 32% consumed them daily, a level of category familiarity that rivals mainstream vitamins. That awareness has since deepened, particularly in Asia-Pacific markets where preventive healthcare philosophies are culturally embedded.
Expansion of Next-Generation Probiotic Strains Research interest in advanced strains such as Akkermansia muciniphila and Faecalibacterium prausnitzii is intensifying. These next-generation and genetically modified probiotics offer more targeted health interventions than conventional strains, creating new premium product categories and expanding the clinical addressable market. In September 2024, Persephone Biosciences launched a synbiotic product for infants and toddlers specifically designed to restore gut microbiome balance, a product category that clinical data now actively supports.
Regulatory Advancements for Specialty Supplements Governments and food safety agencies across Asia-Pacific and North America are developing clearer registration pathways for complex probiotic products. These regulatory advances reduce time-to-market for novel formulations and increase investor confidence in the specialty supplements segment, which carries a projected CAGR of 9.6%, the fastest growth rate within the dietary supplements category.
Growth of Online Retail Distribution Digital commerce is reshaping how consumers discover and purchase probiotic products. Online stores are the fastest-growing distribution channel in this market, enabling consumers to compare formulations, read clinical evidence, and access subscription-based delivery, features that traditional brick-and-mortar pharmacy and supermarket channels cannot match at scale.
Infant and Children’s Gut Health as an Emerging Focus Clinical evidence is building around early microbiome intervention. A decentralized trial evaluating 412 US infants found that approximately 25% lacked detectable Bifidobacterium, a finding that has mobilized companies to develop targeted infant probiotic products. The children and infants segment is forecast to grow faster than the adult segment through 2035, reflecting growing physician endorsement and parental health awareness.
Market Segmentation: Foods and Beverages Lead, Specialty Supplements Accelerate
The probiotics market divides into four primary product categories: foods and beverages, probiotic dietary supplements, animal feed, and other probiotics. Foods and beverages commands nearly 80% of total market share in 2025, a dominance rooted in consumer accessibility, broad retail distribution, and the fact that fermented foods and functional beverages require no prescription. Within this category, fermented foods hold approximately 40% of the overall market, while the non-dairy products sub-segment is growing faster than its dairy counterpart.
Within the dietary supplements category, nutritional supplements capture roughly 60% of segment revenue. However, specialty supplements are outpacing the broader category, growing at a 9.6% CAGR. Adults currently account for approximately 80% of the human end-user segment, but the children and infants segment is attracting disproportionate investment and product launches. By ingredient type, bacterial strains dominate over yeast-based formulations and will continue to do so through the forecast horizon. Hypermarkets and supermarkets remain the leading distribution channel by volume, while online stores are gaining share at the fastest pace.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/probiotics-market/request-quote.html
Regional Insights: Asia-Pacific Commands Nearly Half the Market
Asia-Pacific accounts for 47% of global probiotics market revenue in 2025 and holds the top position among all geographic regions. The region’s leadership reflects deep cultural familiarity with fermented foods, high baseline consumption of dairy and non-dairy probiotic formats, and favorable regulatory conditions that support the registration of novel probiotic strains. Consumer-level awareness of microbiome health is measurably higher in key Asian markets compared to Western counterparts, and this translates directly into purchasing behavior across food, supplement, and specialty product formats.
North America holds the second-largest regional share. US consumer familiarity with probiotics is broad, as the IFIC survey data confirms, and the market benefits from an established retail infrastructure and growing physician-guided supplement recommendations. Europe, home to several of the market’s largest commercial players, contributes meaningfully to both revenue and innovation, with a concentration of probiotic developers headquartered across Western Europe.
The Middle East and North Africa region is forecast to post the highest regional CAGR through 2035. Rising disposable incomes, growing urban health awareness, and expanding modern retail formats in markets such as UAE and Saudi Arabia are driving this acceleration from a lower base.
Competitive Landscape: Large FMCG Players Coexist With Specialized Innovators
The key companies profiled in the Roots Analysis probiotics market report include AB-BIOTICS, ADM, Arla Foods, BioGaia, Danone, General Mills, i-Health, IFF, Kerry, Lallemand, Lifeway Foods, Meiji, Morinaga Milk, Mother Dairy, Nestlé, Novonesis (formed by the merger of Novozymes and Chr. Hansen), Probi, Velbiom, Winclove Probiotics, and Yakult Honsha.
The competitive structure combines large FMCG players such as Nestlé and Danone with dedicated probiotic specialists like BioGaia, Probi, and Novonesis. The main battleground is increasingly research-driven: companies are differentiating through strain specificity, clinically validated health claims, and synbiotic formulations that combine probiotics with prebiotics or fiber to amplify efficacy. A number of leading players are headquartered in Europe, and the market shows no sign of consolidating toward a single dominant architecture; instead, specialized innovators are carving out sustainable positions in therapeutic, pediatric, and women’s health sub-categories.
Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/probiotics-market.html
Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
This release was published on openPR.